Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peptilogics
With
Biomedical Advanced Research and Development Authority
Wellcome Trust
Peptilogics, Inc. is developing PLG0206 for the treatment of PJIs. PLG0206 is an engineered antibacterial peptide (EAP) based on naturally-occurring antimicrobial peptides (AMPs). Recent work on PLG0206 has documented that PLG0206 is a highly effective anti-biofilm agent, in addition to its established activity against planktonic staphylococcus, both in vitro and in a murine animal model of PJI.
PLG0206 will be investigated in this study for treatment of PJI in conjunction with the DAIR procedure followed by the 6-week course of antimicrobial therapy that is standard-of-care (SOC) in this indication.
Patients will be followed for approximately 1 year post treatment.
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with well-fixed prosthesis;
Patients who have a pre- or intra-operative diagnosis of TKA-PJI
You may not be if
Patients for whom a DAIR procedure is not indicated;
Patients with loose prosthesis and/or surgical treatment requiring removal of well-fixed, non-modular implants at screening;
Patients with previous history or presence of osteomyelitis in the index limb;
Patients who have uncontrolled diabetes mellitus;
Patients with body mass index \>50 kg/m2 at screening;
Patients who are immunosuppressed;
Patients who require therapeutic anticoagulation and/or antiplatelet therapy